Pharma Rep Focus

After Pfizer offers discount, NICE gives thumbs up to breast cancer drug Talzenna

Fierce Pharma

JANUARY 18, 2024

Six months after England’s National Institute for Health and Care Excellence (NICE) spurned Pfizer’s breast cancer treatment Talzenna (talazoparib) because it was not cost effective, the agency has | Six months after England’s National Institute for Health and Care Excellence spurned Pfizer’s breast cancer treatment Talzenna because it was not cost (..)

NICE poised to reject AstraZeneca, Daiichi’s Enhertu in HER2-low breast cancer

Fierce Pharma

SEPTEMBER 27, 2023

NICE poised to reject AstraZeneca, Daiichi’s Enhertu in HER2-low breast cancer aliu Wed, 09/27/2023 - 10:40

Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICE

Fierce Pharma

MAY 22, 2023

Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICE zbecker Mon, 05/22/2023 - 10:44

NICE recommends Novartis precision brain cancer treatment

European Pharmaceutical Review

APRIL 24, 2024

in clinical trials [the combination treatment was shown] to halt tumour growth for low-grade gliomas for an average of more than two years” The National Institute for Health and Care Excellence (NICE) has recommended a new targeted drug combination treatment for young people with BRAF V600E mutation-positive glioma.

Medicine

Medicine Pharmaceutical Patients

Surprise Enhertu rejection follows NICE process change

pharmaphorum

MARCH 5, 2024

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.

England's NICE backs Pfizer's Vydura as treatment for acute migraines

Fierce Pharma

SEPTEMBER 13, 2023

Less than four months after recommending Pfizer’s Vydura (rimegepant) to prevent m | Less than four months after recommending Pfizer’s Vydura (rimegepant) to prevent migraine headaches, England’s National Institute of Care and Health Excellence (NICE) has given it a thumbs up to treat them. for episodic (acute) migraine attacks.

Patients

NICE backs AbbVie’s oral therapy for migraine prevention

pharmaphorum

APRIL 11, 2024

AbbVie’s Aquipta has become the first oral therapy for chronic and episodic migraine prevention to be recommended by NICE for NHS use.

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

FEBRUARY 29, 2024

The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.

Pharmaceutical

Pharmaceutical Manufacturing Patients

NICE recommends first medicine for severe alopecia areata

European Pharmaceutical Review

FEBRUARY 22, 2024

The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. Its mechanism of action is such that it reduces inflammation-causing enzymes and subsequent hair loss at the follicle, NICE explained. “I

Medicine

Medicine Healthcare Healthcare Leads

NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio

Fierce Pharma

NOVEMBER 16, 2022

NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio. Wed, 11/16/2022 - 09:44.

AstraZeneca, Amgen's asthma launch Tezspire picks up backing from England's NICE

Fierce Pharma

MARCH 28, 2023

AstraZeneca, Amgen's asthma launch Tezspire picks up backing from England's NICE esagonowsky Tue, 03/28/2023 - 15:00

Jazz wins reimbursement nod from NICE for cannabinoid med Epidyolex

Fierce Pharma

FEBRUARY 1, 2023

Jazz wins reimbursement nod from NICE for cannabinoid med Epidyolex kdunleavy Wed, 02/01/2023 - 10:19

Pfizer’s migraine medicine recommended by NICE

European Pharmaceutical Review

SEPTEMBER 14, 2023

Rimegepant (Vydura) is the “first and only NICE-recommended medicine that can help alleviate the misery of acute migraines, and may be considered a step-change in treatment,” shared Helen Knight, Director of medicines evaluation at the National Institute for Health and Care Excellence (NICE).

Medicine

Medicine Patients Pharmaceutical

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

Fierce Pharma

JANUARY 25, 2023

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE fkansteiner Wed, 01/25/2023 - 18:51

England's NICE signs off on PTC Therapeutics' $3.7M gene therapy for ultra-rare disease

Fierce Pharma

MARCH 23, 2023

England's NICE signs off on PTC Therapeutics' $3.7M gene therapy for ultra-rare disease zbecker Thu, 03/23/2023 - 13:47

NICE recommends Roche biologic for lymphoma

European Pharmaceutical Review

OCTOBER 17, 2023

In final guidance , the National Institute for Health and Care Excellence (NICE) has recommended glofitamab as a new treatment option for advanced lymphoma. NICE “welcome the news that NHS England will make this available to patients quickly,” Knight added. According to NICE, over 700 people could benefit from Roche’s glofitamab.

Medicine

Medicine Engineering Healthcare Healthcare

Alnylam, PTC Therapeutics rare disease drugs win backing from England's NICE

Fierce Pharma

JANUARY 19, 2023

Alnylam, PTC Therapeutics rare disease drugs win backing from England's NICE zbecker Thu, 01/19/2023 - 11:53

NICE puts kibosh on Mounjaro coverage over GLP-1 comparison and cost model uncertainties

Fierce Pharma

JUNE 27, 2023

England’s National Institute for Health and Care Excellence (NICE) on Tuesday said more evidence is needed on the clinical efficacy and cost-effectiveness of Mounjaro, also known as tirzepatide, before the health technology assessor can recommend Lilly's dual GIP/GLP-1 drug for use by the country’s National Health Service (NHS).

Patients

NICE backs wider NHS use of multiple myeloma drug Nexpovio

pharmaphorum

APRIL 22, 2024

NICE backs wider NHS use of multiple myeloma drug Nexpovio Phil.Taylor Mon, 22/04/2024 - 10:58 Bookmark this

NICE no follows Scottish aye for rare disease drug Xenpozyme

pharmaphorum

MARCH 6, 2024

NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the UK will depend on a patient’s address.

NICE recommends innovative breast cancer drug

European Pharmaceutical Review

JANUARY 19, 2024

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations.

Pharmacology

Pharmacology Patients Pharmaceutical Medicine

NICE backs Pfizer’s Talzenna for advanced breast cancer

pharmaphorum

JANUARY 18, 2024

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.

Remote Parkinson’s monitoring tech backed by NICE

pharmaphorum

JANUARY 25, 2024

NICE firms up guidance backing NHS use of five digital health wearables for remote monitoring of Parkinson's disease patients

Patients

With NICE nod, Gilead clears another regulatory hurdle in Europe for Hepcludex

Fierce Pharma

MAY 15, 2023

With NICE nod, Gilead clears another regulatory hurdle in Europe for Hepcludex kdunleavy Mon, 05/15/2023 - 09:30

NICE signs off on Merck's Keytruda for early-stage triple negative breast cancer

Fierce Pharma

NOVEMBER 8, 2022

NICE signs off on Merck's Keytruda for early-stage triple negative breast cancer. Tue, 11/08/2022 - 11:10.

NICE recommends combination therapy for prostate cancer

European Pharmaceutical Review

DECEMBER 21, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone, for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy.

Food and Drug Administration

Food and Drug Administration Food Patients FDA

UK access disparity resolved as NICE backs RCC therapy

pharmaphorum

MARCH 7, 2024

NICE decision on Ipsen’s Cabometyx and MSD’s Keytruda in first-line kidney cancer ends a disparity in access within the UK.

UK NICE recommends Pfizer’s talazoparib for advanced breast cancer

Pharmaceutical Technology

JANUARY 22, 2024

The UK NICE recommends Pfizer's talazoparib, marketed as Talzenna, to treat a specific type of locally advanced or metastatic breast cancer.

Marketing

NICE backs digital technologies for COPD rehab

pharmaphorum

DECEMBER 21, 2023

NICE backs NHS use of digital COPD rehab programmes, myCOPD and SPACE for COPD, as an alternative to face-to-face consultations

Consulting

NICE expands access to Paxlovid amid over-supply

pharmaphorum

JANUARY 11, 2024

NICE has extended the NHS availability of Pfizer’s COVID-19 drug Paxlovid as millions of doses approach their expiry date

NICE recommends first Parkinson’s treatment

European Pharmaceutical Review

OCTOBER 26, 2023

The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s foslevodopa–foscarbidopa (Produodopa) as a treatment option for advanced Parkinson’s. This is the first technology appraisal from NICE to look at a treatment for Parkinson’s. The treatment is administered by an infusion pump over 24 hours.

Medicine

Medicine Management Pharmaceutical Patients

First NICE-recommended treatment for chronic heart failure

European Pharmaceutical Review

MAY 19, 2023

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. Therefore, NICE’s final draft guidance for this indication is welcomed by the industry.

Medicine

Medicine Patients Leads Pharmaceutical

AbbVie’s Tepkinly backed by NICE for DLBCL patients

pharmaphorum

JANUARY 31, 2024

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9

Patients

Patients Medicine

NICE backs two AIs for stroke diagnosis in NHS

pharmaphorum

JANUARY 23, 2024

Two artificial intelligence-powered software tools – e-Stroke and RapidAI – have been recommended for use in the NHS to help detect stroke from CT brain scans by NICE.

NICE recommends new Fabry disease treatment

European Pharmaceutical Review

SEPTEMBER 4, 2023

The National Institute for Health and Care Excellence (NICE) has recommended Chiesi’s Elfabrio ® (pegunigalsidase alfa) for Fabry disease (alpha-galactosidase deficiency) in adults. The post NICE recommends new Fabry disease treatment appeared first on European Pharmaceutical Review.

Medicine

Medicine Safety Patients Medical

UK NICE recommends use of AbbVie’s Parkinson’s treatment

Pharmaceutical Technology

OCTOBER 27, 2023

The UK NICE has recommended the use of AbbVie’s foslevodopa–foscarbidopa (Produodopa) for the treatment of advanced Parkinson’s disease.

NICE recommends new type 2 diabetes treatment

European Pharmaceutical Review

SEPTEMBER 8, 2023

National Institute for Health and Care Excellence (NICE) final draft guidance recommends tirzepatide as a new treatment option for this indication. The post NICE recommends new type 2 diabetes treatment appeared first on European Pharmaceutical Review.

Food and Drug Administration

Food and Drug Administration Medicine Food Manufacturing

NICE recommends Lilly’s tirzepatide to treat T2D

Pharmaceutical Technology

SEPTEMBER 8, 2023

The UK NICE has recommended Eli Lilly’s tirzepatide for the treatment of adult patients with inadequately controlled type 2 diabetes.

Patients

UK’s NICE recommends Pfizer’s rimegepant to treat migraine

Pharmaceutical Technology

JUNE 1, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer ’s rimegepant (Vydura) to prevent migraine attacks. NICE medicines evaluation director Helen Knight said: “Each year, the lives of millions of people in England are blighted by migraine attacks.

Side effects

Side effects Consulting Education Medicine

NICE recommends oral migraine treatment for first time

European Pharmaceutical Review

JUNE 1, 2023

An oral treatment for preventing migraines has been recommended by the National Institute for Health and Care Excellence (NICE) for the first time. The NICE final draft guidance recommends rimegepant in individuals who have at least four migraine attacks per month but less than 15, stated the UK regulatory body.

Side effects

Side effects Medicine Medical Pharmaceutical

NICE recommends Eli Lilly ulcerative colitis biologic

European Pharmaceutical Review

SEPTEMBER 22, 2023

The National Institute for Health and Care Excellence (NICE) have for the first time, recommended a IL-23p19 targeted biologic for adults with moderate to severe active ulcerative colitis in Great Britain. The post NICE recommends Eli Lilly ulcerative colitis biologic appeared first on European Pharmaceutical Review.

Patients

Patients Medicine Pharma Management

NICE says no to Lynparza in prostate cancer, creating UK access divide

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. In particular, the ICR claims NICE’s review committee factored in the cost of testing for BRCA mutations in its calculations.

Manufacturing

Manufacturing Patients Marketing

NICE backs pump-based Parkinson’s drug from AbbVie

pharmaphorum

OCTOBER 26, 2023

NICE backs pump-based Parkinson’s drug from AbbVie Phil.Taylor Thu, 26/10/2023 - 10:14 Bookmark this

UK NICE recommends zanubrutinib for Waldenstrom’s macroglobulinaemia

Pharmaceutical Technology

OCTOBER 3, 2022

The UK National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option to treat Waldenstrom’s macroglobulinaemia (WM) patients. The post UK NICE recommends zanubrutinib for Waldenstrom’s macroglobulinaemia appeared first on Pharmaceutical Technology.

Patients

Patients Pharmaceutical

After Pfizer offers discount, NICE gives thumbs up to breast cancer drug Talzenna

NICE poised to reject AstraZeneca, Daiichi’s Enhertu in HER2-low breast cancer

Trending Sources

Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICE

NICE recommends Novartis precision brain cancer treatment

Surprise Enhertu rejection follows NICE process change

England's NICE backs Pfizer's Vydura as treatment for acute migraines

NICE backs AbbVie’s oral therapy for migraine prevention

NICE recommends first licenced treatment for AL amyloidosis

NICE recommends first medicine for severe alopecia areata

NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio

AstraZeneca, Amgen's asthma launch Tezspire picks up backing from England's NICE

Jazz wins reimbursement nod from NICE for cannabinoid med Epidyolex

Pfizer’s migraine medicine recommended by NICE

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

England's NICE signs off on PTC Therapeutics' $3.7M gene therapy for ultra-rare disease

NICE recommends Roche biologic for lymphoma

Alnylam, PTC Therapeutics rare disease drugs win backing from England's NICE

NICE puts kibosh on Mounjaro coverage over GLP-1 comparison and cost model uncertainties

NICE backs wider NHS use of multiple myeloma drug Nexpovio

NICE no follows Scottish aye for rare disease drug Xenpozyme

NICE recommends innovative breast cancer drug

NICE backs Pfizer’s Talzenna for advanced breast cancer

Remote Parkinson’s monitoring tech backed by NICE

With NICE nod, Gilead clears another regulatory hurdle in Europe for Hepcludex

NICE signs off on Merck's Keytruda for early-stage triple negative breast cancer

NICE recommends combination therapy for prostate cancer

UK access disparity resolved as NICE backs RCC therapy

UK NICE recommends Pfizer’s talazoparib for advanced breast cancer

NICE backs digital technologies for COPD rehab

NICE expands access to Paxlovid amid over-supply

NICE recommends first Parkinson’s treatment

First NICE-recommended treatment for chronic heart failure

AbbVie’s Tepkinly backed by NICE for DLBCL patients

NICE backs two AIs for stroke diagnosis in NHS

NICE recommends new Fabry disease treatment

UK NICE recommends use of AbbVie’s Parkinson’s treatment

NICE recommends new type 2 diabetes treatment

NICE recommends Lilly’s tirzepatide to treat T2D

UK’s NICE recommends Pfizer’s rimegepant to treat migraine

NICE recommends oral migraine treatment for first time

NICE recommends Eli Lilly ulcerative colitis biologic

NICE says no to Lynparza in prostate cancer, creating UK access divide

NICE backs pump-based Parkinson’s drug from AbbVie

UK NICE recommends zanubrutinib for Waldenstrom’s macroglobulinaemia

Stay Connected